Chronic rhinosinusitis (CRS) is a condition of persistent sinonasal mucosal inflammation
which affects 11.9% of the US population. Mepolizumab is newly approved to treat chronic
rhinosinusitis with nasal polyps (CRSwNP, the spaces inside nose and head are swollen and
inflamed) and acts booking interleukin-5 (IL-5) a protein implicated in the inflammatory
process. We aim to use Single-cell RNA sequencing (RNA-Seq, a method of genetically
'barcoding' cells to allow gene expression to be profiled at the level of individual cells)
to study the effects of IL-5 blockade on the generation and maintenance of nasal adaptive
immune responses, in CRS subjects.